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N-Substituted Nipecotic Acids as (S)-SNAP-5114 Analogues
with Modified Lipophilic Domains
Michael C. Böck,[a] Georg Höfner,[a] and Klaus T. Wanner*[a]
Dedicated to Prof. Dr. Theodor Severin on the occasion of his 90th birthday.
Potential mGAT4 inhibitors derived from the lead substance (S)-
SNAP-5114 have been synthesized and characterized for their
inhibitory potency. Variations from the parent compound
included the substitution of one of its aromatic 4-methoxy and
4-methoxyphenyl groups, respectively, with a more polar
moiety, including a carboxylic acid, alcohol, nitrile, carboxamide,
sulfonamide, aldehyde or ketone function, or amino acid partial
structures. Furthermore, it was investigated how the substitu-
tion of more than one of the aromatic 4-methoxy groups affects
the potency and selectivity of the resulting compounds. Among
the synthesized test substances (S)-1-{2-[(4-formylphenyl)bis(4-
methoxyphenyl)-methoxy]ethyl}piperidine-3-carboxylic acid,
that features a carbaldehyde function in place of one of the
aromatic 4-methoxy moieties of (S)-SNAP-5114, was found to
have a pIC50 value of 5.89�0.07, hence constituting a slightly
more potent mGAT4 inhibitor than the parent substance while
showing comparable subtype selectivity.
Introduction
The neuronal signal transduction in the mammalian central
nervous system (CNS) is regulated by a complex equilibrium of
various excitatory and inhibitory neurotransmitters. γ-Amino-
butyric acid (GABA) is the most abundant of the latter,[1] with
approximately 40% of synapses estimated to be GABAergic.[2]
Pathologically deficient GABA release into the synaptic cleft
results in attenuation of the inhibitory component, which is
associated with a variety of severe neurological disorders
including epilepsy,[3,4] neuropathic pain,[5] anxiety disorders,[6]
depression,[6,7] and Alzheimer’s disease.[8] A promising approach
to the treatment of these disorders is the application of drugs
that inhibit the GABA reuptake[8,9,10,11] into the presynaptic
neurons and the surrounding glial cells, respectively, thereby
enhancing the GABA concentration in the synaptic cleft and
thus prolonging the effect of the released GABA. The specific
and high affinity membrane based[12] transport proteins accom-
plishing the GABA reuptake (GATs) are thus an important
therapeutic target. Belonging to the solute carrier 6 (SLC6)
family,[13] they consist of 12 transmembrane helices, four of
which (TM 1, TM3, TM6 and TM8) form the inner ring that in its
center halfway across the cell membrane holds the central
substrate binding site S1. Separated from the S1 binding site by
the extracellular gate a second substrate binding site exists at
the bottom of the extracellular vestibule, termed S2,[12] the
occupation of which is assumed to trigger the conformational
changes necessary for the release of the substrate from the S1
pocket into the cell.[14] Four GAT subtypes have been identified,
termed GAT1, GAT2, GAT3, and BGT1 in accordance with the
nomenclature proposed by the Gene Nomenclature Committee
of the Human Genome Organisation (HUGO),[15] or, when cloned
from mouse brain, mGAT1 (=^GAT1), mGAT2 (=^BGT1), mGAT3
(=^GAT2) and mGAT4 (=^GAT3).[16,17] Since the biological test
system developed in our group is based on GABA transporters
cloned from mouse cells, in this paper the corresponding
nomenclature will be used.
The predominant GABA transporter in the mammalian CNS,
mGAT1, is located primarily in pre-synaptic neuronal
membranes,[18] with its highest densities found in neocortex,
spinal cord, brainstem, cerebellum, basal ganglia, and
hippocampus.[2,19] As the occurrence of mGAT2 and mGAT3 in
the CNS is restricted to low densities in specific brain structures,
these subtypes play only a marginal role in the termination of
the cerebral GABAergic neurotransmission.[20,21] mGAT4 is the
second most abundant GABA transporter after mGAT1 and
found particularly in olfactory bulb, brainstem, and
diencephalon,[22] where it is most commonly expressed on glia
cells.[18] The selective targeting of mGAT4 may therefore provide
the possibility of treating neurological disorders associated with
these brain regions with minimal impairment of the GABA
reuptake in other parts of the CNS. Compared to mGAT1-
selective inhibitors such as Tiagabine (Gabatril®) (1, Table 1,
entry 1), adverse effects, including dizziness, somnolence, head-
ache, memory loss, and tremor,[23] could hence be possibly
reduced, resulting in more tolerable medication and better
patient compliance.
(S)-SNAP-5114 (S)-2 (Table 1, entry 3) can be considered the
benchmark mGAT4 inhibitor. Since its publication,[24] it has been
the prototype for the development of further mGAT4 inhibitors
with the goal of increasing potency, subtype selectivity, and
chemical stability. The structural modifications implemented in
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the (S)-SNAP-5114 scaffold so far include variations of the
spacer between the nipecotic acid partial structure and the
trityl rest, as it is for example the case with DDPM-1457 3
(Table 1, entry 4),[25] resulting in compounds with enhanced
stability due to the labile trityl ether function being avoided.
Variations of the substitution pattern of the trityl structure, e.g.
by introduction of an additional methyl group in the 2-position
of one of the three aryl residues (4, Table 1, entry 5), was found
to lead to compounds with slightly improved subtype selectiv-
ity. Unfortunately, the moderate potency inherent to the parent
compound (S)-2, which is characterized by a pIC50 value of
5.71�0.07 (Table 1, entry 3), remains largely unaffected by
these structural modifications. This underlines the necessity of
further research in order to advance the general understanding
of the structure activity relationship (SAR) of mGAT4 inhibitors.
To this end, the present study aims at the synthesis of (S)-
SNAP-5114 [(S)-2] analogues that feature a more polar moiety
in place of one of the methoxy groups present in the trityl rest
of the parent compound (S)-2 (Scheme 1, a). As such polar
moieties carboxylic acid, alcohol aldehyde, nitrile, carboxamide,
sulfonamide, aldehyde or ketone functions were taken into
consideration, as well as amino acid partial structures. These
modifications might result in increased polar interactions of the
inhibitor with the target, thus possibly affecting its potency and
subtype selectivity. In that context, we also aimed to clarify how
a wider variation of the original (S)-SNAP-5114 [(S)-2] structure,
comprising the replacement of one entire 4-methoxyphenyl
moiety of the trityl residue by a polar group (Scheme 1, d),
would influence the biological activity. A further question
addressed with this study is how the inhibitory potency of (S)-
SNAP-5114 [(S)-2] analogues that have two (Scheme 1, b) or all
three (Scheme 1, c) 4-methoxy groups in the trityl moiety of (S)-
2 substituted with other residues compare to inhibitors with
only one such alteration. The findings would allow to draw
conclusions about the SAR of mGAT4 inhibitors with regard to
polarity, size, and number of matching substituents in the
aromatic domain, and therefore point out important aspects to
consider in future development of more potent mGAT4-
inhibitors.
Results and Discussion
Chemistry
Synthesis of the desired (S)-SNAP-5114 [(S)-2] analogues was
performed according to the reaction sequence shown in
Scheme 2 that had been described by Schirrmacher et al.[27] for
the preparation of [18F] labelled (S)-SNAP-5114 analogues.
According to this plan, the respective tertiary alcohols 8
exhibiting the desired polar function attached to the aryl
moieties, or suitable precursors thereof, are transformed into
the corresponding trityl chlorides, which can e.g. be accom-
plished by reaction with acetyl chloride. Subsequent treatment
of the prepared trityl chlorides 7 with N-(2-hydroxyethyl)
Table 1. Binding affinities (pKi) and inhibitory potencies (pIC50) of reference compounds 1–5 from the literature.
Entry Compound pKi
[a] pIC50
[b]
mGAT1 mGAT1 mGAT2 mGAT3 mGAT4
1 Tiagabine [(R)-1][d] 7.43�0.11 6.88�0.12 50% 64% 73%
2 rac-SNAP-5114 [rac-2] [c] – 4.08 – 4.96 5.64�0.05
3 (S)-SNAP-5114 [(S)-2] [c] 4.56�0.02 4.07�0.09 56% 5.29�0.04 5.71�0.07
4 DDPM-1457 [(S)-3] [d] 4.33�0.06 4.40�0.05 4.42�0.11 5.47�0.02 5.87�0.08
5 DDPM-859 [(S)-4] [d] – 4.19�0.07 4.12�0.08 4.85�0.04 5.78�0.03
[a] Results of the MS Binding Assays are given as pKi�SEM. [b] Results of the [
3H]GABA uptake assays are given as pIC50�SEM. Percent values represent
remaining [3H]GABA uptake in presence of 100 μM compound. [c] Reference literature [25]. [d] Reference literature [26].
Scheme 1. Overview of the structural modifications of (S)-SNAP-5114 con-
ducted in this study.
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nipecotinate 6, which may be prepared according to
literature,[28] will furnish the fully assembled target compounds
in form of their carboxylic acid esters and finally the free
nipecotic acids 5 upon hydrolysis of the carboxylic acid ester
function. Although the stereochemistry of the nipecotic acid
partial structure is known to play a decisive role in the
biological activity of mGAT4 inhibitors,[24] we opted for the
synthesis of racemic compounds for economic reasons. How-
ever, for those racemic compounds showing equal or higher
activity than (S)-SNAP-5114 in the biological testing, additionally
the (R)- and (S)-isomers should be synthesized and evaluated
for their biological activity. To achieve the synthesis of these
enantiopure compounds following the depicted synthetic path-
way (Scheme 2), only rac-6 has to be replaced by its (R)- and (S)-
isomer, respectively.
Synthesis of the tertiary alcohols 8a–k
Initially for the construction of the target compounds 5a–i in
which one or more of the three methoxy substituents of (S)-
SNAP-5114 [(S)-2] are replaced by an alternative polar moiety
(compound type a-c in Scheme 1), the corresponding tertiary
alcohols 8a-i had to be synthesized (Table 2, entry 1–9, Table 3,
entry 9). This was accomplished by transforming aryl halides
9a–h into the corresponding Grignard or organolithium
reagents, which were subsequently reacted with the appropri-
ate electrophiles, i. e. with 4,4’-dimethoxybenzophenone (10a,
Table 2, entry 1–6), 4-cyanobenzoyl chloride (10b, Table 2,
entry 7), methyl 4-methoxybenzoate (10c, Table 2, entry 8), and
dimethyl carbonate (10d, Table 2, entry 9). This led to the
differently substituted trityl alcohols 8a–i in acceptable to good
yields of 53%–99%, most of which exhibit two of the three 4-
methoxyphenyl units present in (S)-SNAP-5114 [(S)-2] together
with a third aryl moiety with a different structure (Table 2, entry
1–7). Trityl alcohol 8 j (Table 3, entry 9), featuring an amide
group and two methoxy groups, respectively, in the 4-position
of the three aromatic moieties, was obtained in a yield of 96%
by hydration of the nitrile function of 8g (Table 2, entry 7),
which was accomplished by the treatment with potassium tert-
butoxide in tert-butanol, following a general procedure from
the literature.[29] 4,4’-Dimethoxybenzilic acid methyl ester 8k
(Table 3, entry 10) as precursor for the preparation of com-
pounds of type d (Scheme 1) was synthesized by benzylic acid
rearrangement of 4,4’-dimethoxybenzil,[30] followed by esterifi-
cation with methyl iodide in analogy to a method published for
benzylic acid.[31]
Construction of target compounds 5a–l from
N-(2-hydroxyethyl)nipecotic acid ethyl ester 6 and tertiary
alcohols 8a–l
The synthesis of the target compounds 5a–k should be
achieved by etherification of the hydroxy function of N-(2-
hydroxyethyl)nipecotic acid ethyl ester 6 with the tertiary
alcohols 8a–k that had been prepared for this purpose. To this
end, in the first step alcohols 8a–k were transformed into the
corresponding tertiary chlorides 7a–k by reaction with acetyl
chloride in the presence of a catalytic amount of dimethyl
formamide (Table 3, step a). Under these conditions, also the
acetal function of 8a was completely transformed in an
aldehyde group as wanted. Therefore, the reaction mixture
obtained after treatment of 8a with acetyl chloride, resulting in
7a with the deprotected aldehyde function, could be directly
used for the next step, the etherification reaction with N-(2-
hydroxyethyl)nipecotic acid ethyl ester (6). In contrast, the more
stable acetal function of 8b was only partially transformed into
the ketone under the conditions for the halide formation.
Hence, 8b was first transformed into ketone 11 by refluxing in
aqueous acid (93% yield), which was subsequently converted in
chloride 7b. Due to their high reactivity and susceptibility to
hydrolysis upon exposure to moisture, the tertiary chlorides
were directly used without prior purification or characterization
for the next step, the alcoholysis with racemic 1-(2-hydroxyeth-
yl)nipecotic acid ethyl ester (6) (Table 3, step b). The desired
products 12a–k with the newly created trityl ether function
were thus obtained in yields from 42% to 88% over both
reaction steps (based on 8a–k as starting material).
For the synthesis of an analogue of rac-SNAP-5114 [(S)-2]
that features a hydroxyl function in place of one of the 4-
methoxyphenyl groups, we decided to use a propyl instead of
the ethoxy linker to warrant chemical stability of the product.
The synthesis was accomplished by reacting anisyl lithium with
ethyl 4-chlorobutanoate to give the required alcohol 8 l with an
γ-chloropropyl residue, which upon reaction with ethyl nipeco-
tinate led to the desired N-substituted nipecotic acid ester 12 l
in 66% yield (Table 3, step c).
In order to obtain the free nipecotic acid derivatives 5a–l,
compounds 12a–l were treated with barium hydroxide octahy-
drate in methanol/water 4 :1 for the hydrolysis of the ester
function, followed by workup with carbon dioxide (Table 3, step
d). Thereupon, the target compounds 5a–l could be isolated in
yields from 61% to 97%.
Synthesis of target compounds 5m–t with amino acid
derived residues substituting one of the three methoxy
groups in (S)-SNAP-5114 [(S)-2]
Next, we aimed at the synthesis rac-SNAP-5114 analogues that
feature a hydroxy methyl moiety or an amino acid subunit as a
Scheme 2. Retrosynthetic analysis for the preparation of (S)-SNAP-5114
analogues
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polar group replacing one of the three methoxy residues in the
lipophilic domain of (S)-SNAP-5114 [(S)-2]. As starting material
for the synthesis compound 12a, a nipecotic acid derivative
with one of the three methoxy groups of the trityl moiety
having been replaced by a formyl residue was used. Reduction
of the aldehyde function in 12a was accomplished by treat-
ment with sodium borohydride in methanol, providing the
corresponding alcohol 12m in a yield of 89% (Table 4, entry 1).
Reductive amination of the aldehyde function in 12a was
performed employing a set of amino acids and amino acid ester
hydrochlorides (Table 4, entry 2–8). Upon application of a
slightly modified standard method[32] employing sodium acetox-
yborohydride in dichloromethane as reductant (instead of
dichloroethane) to 12a and the respective amino acid ester
hydrochlorides led to the glycine methyl ester 12n, β-alanine
ethyl ester 12o, 1-aminocyclopropane-1-carboxylic acid ethyl
ester 12p, and 2-amino-2-methylpropanoic acid ethyl ester
derivatives 12q (Table 4, entry 2–5) in yields of 42 to 64%. The
γ-aminobutyric acid ethyl ester derivative of 12a could not be
obtained by this procedure since the product underwent partial
γ-lactamization during workup, resulting in a mixture of the
desired compound and the corresponding γ-butyrolactam.
Table 2. Synthesis of the trityl alcohols 2a–i.
Entry Aryl halide Metal-ation reagent Electrophile Product R1 R2 R3 Yield [%]
1 9a t-BuLi 10a 8a   CH(OMe)2   OMe   OMe 99
2 9b t-BuLi 10a 8b   OMe   OMe 87
3 9c[b] t-BuLi 10a 8c   SO2NMe2   OMe   OMe 53
4 9d n-BuLi 10a 8d   OMe   OMe 56
5 9e i-PrMgCl 10a 8e   COOEt   OMe   OMe 77
6 9 f Mg 10a 8f   CH2OMe   OMe   OMe 92
7 9g Mg 10b 8g   CN   OMe   OMe 94
8 9 f Mg 10c 8h   CH2OMe   CH2OMe   OMe 70
9 9 f Mg 10d 8 i   CH2OMe   CH2OMe   CH2OMe 85
Reagents and conditions: [a] entry 1–3: t-BuLi (2.0 eq), THF,   78 °C, 2 h, 4,4’-dimethoxybenzophenone (1.0 eq), THF,   78 °C-rt; entry 5: i-PrMgCl (1.0 eq), THF,
  20 °C, 1.5 h, 4,4’-dimethoxybenzophenone (1.0 eq), THF,   20 °C-rt; entry 6: n-BuLi (1.0 eq), diethyl ether,   78 °C, 0.5 h, 4,4’-dimethoxybenzophenone
(0.83 eq), diethyl ether,   78 °C-rt; entry 7: magnesium (1.0 eq), THF, rt, 4-cyanobenzoylchloride, THF, 0 °C-rt; entry 8: magnesium (1.0 eq), THF, rt, methyl 4-
methoxybenzoate (0.89 eq), THF, reflux; entry 9: magnesium (1.0 eq), THF, rt, dimethyl carbonate (0.33 eq), THF, reflux. [b] Synthesized by N-alkylation of 4-
bromobenzenesulfonamide with dimethyl sulfate (2.0 eq) in presence of potassium carbonate (4.0 eq) and tetrabutylammonium tetrafluoroborate (10 mol%)
under reflux conditions.
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Attempts to reopen the lactam function under basic conditions
(barium hydroxide or sodium hydroxide at rt or reflux) (Table 3,
entry 6) led to a completion of the formation of lactam 5r, or to
cleavage of the ether function when lithium hydroxide was
used under reflux conditions. Hence, the reductive amination of
12a was attempted with the free γ-aminobutyric acid (GABA).
Applying the established reaction conditions did not lead to the
desired product 12s, which is likely to be due to the very low
solubility of GABA in dichloromethane. However, when di-
chloromethane was replaced by methanol and sodium triace-
Table 3. Synthesis of the N-substituted nipecotic acid ethyl esters 12a–k and their hydrolysis to the free nipecotic acid derivatives 5b–k.
Entry Starting
material
R1 R2 R3 Product of
step a+b
R1 Yield
[%][f]
Product
of step d
R1 Yield
[%]
1 8a   OMe   OMe 12a 70 5a 89
2 8b   OMe   OMe 12b 50 5b 86
3 8c   OMe   OMe 12c 64 5c 88
4 8d   OMe   OMe 12d 48 5d 80
5 8e   OMe   OMe 12e 54 5e 61
6 8f   OMe   OMe 12f 44 5f 81
7 8g   OMe   OMe 12g 85 5g 86
8 8h   CH2OMe   OMe 12h 46 5h 94
9 8 i   OMe   CH2OMe 12 i 42 5 i 90
10 8 j   OMe   OMe 12 j 49 5 j 87
11 8k   COOMe   OMe   OMe 12k   COOMe 88 5k   COOH 97
Reagents and conditions: [a] acetyl chloride, dimethyl formamide (cat.), rt; [b] HCl, THF/H2O, reflux; [c] 1-(2-hydroxyethyl)nipecotic acid ethyl ester (6) (1.1 eq),
potassium carbonate (2.5 eq), acetonitrile, rt; [d] barium hydroxide octahydrate (2–4 eq), methanol/water 4 :1; carbon dioxide; [e] ethyl nipecotinate (1.1 eq),
potassium carbonate (2.5 eq), potassium iodide (0.1 eq), acetonitrile, microwave, 80 °C. [f] Yield over two steps.
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toxyborohydride by sodium cyanoborohydride, 12s (Table 4,
entry 7) was formed in a yield of 40%. The same method could
also be successfully applied to the synthesis of p-aminobenzoic
acid derivative 12t (Table 4, entry 8). The free nipecotic acids
5m–q and 5s–t became finally available upon subjecting
compounds 12m–q and 12s–t to alkaline hydrolysis using the
procedure as already described above [Ba(OH)2 · 8 H2O, CO2
workup] for the transformation of compounds 12a–l into 5a–l
(Table 4, step b), the yields of this transformation amounting to
65–96%.
Biological evaluation
The N-substituted nipecotic acids 5a–t, and their ester
precursors 12a–q and 12s–t were tested for their inhibitory
potencies on the four GABA transporter subtypes mGAT1-4 in a
[3H]GABA uptake assay that was previously developed by our
group.[33] The tests were performed in a standardized manner
using HEK293 cell lines, each expressing one of the four tested
GABA transporter subtypes. Furthermore, binding affinities
towards mGAT1 were examined employing a standardized MS
Binding Assay with NO711 as native MS marker.[34] For
compounds that in preliminary experiments did not reduce [3H]
GABA uptake beyond 50% at a test concentration of 100 μM,
which equals a pIC50 of�4.0, only the percent values of the
remaining [3H]GABA uptake are listed. Correspondingly, the
percentage of remaining marker is given in cases when the
tested compound did not cause a reduction of the MS marker
binding beyond 50%, equating to a pKi of�4.0. When [
3H]
GABA uptake or NO711 binding was reduced below 50%, at a
concentration of 100 μM, inhibitory potencies (pIC50 values) and
binding affinities (pKi values) were determined in full scale [
3H]
GABA uptake and MS Binding Assays, respectively, measure-
ments being performed as triplicates. For compounds with
pIC50 ([
3H]GABA uptake assay) or pKi (MS Binding Assays) values
close to or above 5.0, these experiments were repeated twice
and SEM have been calculated. The results are summarized in
Table 5.
As outlined above, the structure of the prototypic mGAT4
inhibitor rac-SNAP-5114 (rac-2) was modified by formally
replacing one of the three aromatic methoxy moieties in its
lipophilic domain with a variety of different functional groups.
For the purpose of estimating the effect that these modifica-
tions exert on the polarity of the resulting molecule, the log D
values of the compounds under physiological conditions (pH=
Table 4. syntesis of the target compounds 5m–t with amino acid derived residues substituting one of the three methoxy groups in (S)-SNAP-5114.
Entry Product of step a R1 Yield [%] Product of step b R2 Yield [%]
1 12m   OH 89 5m   OH 69
2 12n 57 5n 65
3 12o 42 5o 74
4 12p 59 5p 82
5 12q 64 5q 92
6 5r 47[c]
7 12s 40 5s 84
8 12t 25 5t 96
Reagents and conditions: [a] entry 1: sodium borohydride (2.5 eq), methanol, rt; entry 2–5: sodium triacetoxyborohydride (1.4 eq), amino acid ethyl ester
hydrochloride (2.0 eq), dichloromethane, rt; entry 7–8: sodium cyanoborohydride (1.4 eq), free amino acid (2.0 eq), methanol, rt. [b] barium hydroxide
octahydrate (2–4 eq), methanol/water 4 :1; carbon dioxide. [c] Yield over two steps.
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Table 5. Binding affinities (pKi) and inhibitory potencies (pIC50) of the N-substituted nipecotic acids 6a, c–u and nipecotic acid ethyl esters 12a, c–r, t–u.
Entry Compound R1 R2 R3 R4 X pKi
[a] pIC50
[b]
mGAT1 mGAT2 mGAT3 mGAT4
1 12a OMe OMe OEt O 85.4% 55.5% 4.57 4.90 55.9%
2 5a OMe OMe OH O 4.41�0.11 4.17�0.08 66.3% 4.98�0.08 5.77�0.04
3 (S)-5a OMe OMe OH O 77.4% 4.14�0.00 72.6% 5.16�0.05 5.89�0.07
4 (R)-5a OMe Ome OH O 4.91�0.09 4.45�0.08 50.1% 4.47�0.05 4.86�0.03
5 12b OMe OMe OEt O 84.6% 72.9 % 66.4 % 55.2 % 84.2 %
6 5b OMe OMe OH O 4.51�0.03 64.6 % 64.2 % 4.24�0.02 5.43�0.04
7 12c OMe OMe OEt O 93.8% 75.7 % 73.2 % 95.9 % 94.3 %
8 5c OMe OMe OH O 62.1% 67.9 % 78.0 % 77.1 % 82.0 %
9 12d OMe OMe OEt O 77.2% 4.39 4.88 4.71 4.24
10 5d OMe OMe OH O 4.03 84.9% 72.9% 81.8% 4.58
11 12e OMe OMe OEt O 74.8% 84.6% 87.3% 79.0% 76.1%
12 5e OMe OMe OH O 71.4% 96.5% 85.2% 4.24 4.86
13 12f OMe OMe OEt O 55.3% 66.6% 58.8% 56.9% 50.8%
14 5f OMe OMe OH O 89.4% 67.1% 72.7% 4.51�0.08 5.42�0.10
15 12g OMe OMe OEt O 97.6% 76.6 % 80.7 % 63.6 % 71.9 %
16 5g OMe OMe OH O 4.40�0.10 74.8 % 82.9 % 4.31�0.12 5.07�0.12
17 12h CH2OMe OMe OEt O 72.9% 64.9 % 4.30 50.6 % 4.05
18 5h CH2OMe OMe OH O 74.1% 70.5 % 55.2 % 52.2 % 4.77
19 12 i CH2OMe CH2OMe OEt O 87.5% 70.3 % 65.0 % 4.02 51.4 %
20 5 i CH2OMe CH2OMe OH O 92.7% 90.7 % 72.6 % 68.3 % 76.1 %
21 12 j OMe OMe OEt O 89.3% 57.8 % 56.1 % 4.10 60.0 %
22 5 j OMe OMe OH O 87.0% 79.6 % 96.1 % 82.1 % 65.2 %
23 12k   COOMe OMe OMe OEt O 90.8% 89.1 % 92.6 % 64.1 % 78.2 %
24 5k   COOH OMe OMe OH O 96.9% 100% 101 % 94.0 % 96.5 %
25 12 l   OH OMe OMe OEt CH
2
104.0% 79.3% 70.4% 65.0% 73.8%
26 5 l   OH OMe OMe OH CH
2
4.49 69.5% 62.5% 80.7% 92.0%
27 12m OMe OMe OEt O 75.3% 50.4% 49.3% 4.45 4.23
28 5m OMe OMe OH O 55.0% 78.1% 91.6% 58.7% 4.90
29 12n OMe OMe OEt O 91.7% 51.8 % 4.29 4.47 4.18
30 5n OMe OMe OH O 86.2% 81.8 % 96.1 % 90.9 % 72.2 %
31 12o OMe OMe OEt O 72.4% 4.59 4.72 4.63 4.66
32 5o OMe OMe OH O 82.3% 94.4 % 69.5 % 89.1 % 56.3 %
33 12p OMe OMe OEt O 95.8% 75.5 % 103% 58.8% 66.1 %
34 5p OMe OMe OH O 58.8% 78.2 % 76.0 % 69.1 % 4.88
35 12q OMe OMe OEt O 90.9% 66.9 % 67.4 % 49.3 % 57.4 %
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7.4, electrolyte concentration=0.154 mmol/l) were calculated
(clog D: calculated log D) using MarvinSketch.[35]
Replacement of one of the methoxy substituents in the rac-
SNAP-5114 (rac-2) molecule by the larger methoxymethylene
group leads to 5f, which at mGAT4 exhibits a pIC50 value of
5.42�0.10 (Table 5, entry 14). This constitutes only a minor
decrease in inhibitory potency at the transporter compared to
the parent compound rac-2 (pIC50=5.64�0.05, Table 1, en-
try 2), suggesting that a slight increase in the space require-
ments of the substituent is tolerated relatively well by mGAT4.
If a nitrile function is introduced in place of a methoxy moiety,
the loss of potency at mGAT4 is more pronounced, amounting
to a pIC50 value 5.07�0.12 (5g, Table 5, entry 16). Since the
nitrile function is also a hydrogen bridge acceptor and conveys
very similar polarity compared to the methoxy moiety it
replaces (clog D of 5g 2.33, clog D of rac-2 2.32), this finding is
likely attributable to the linear shape of the nitrile function not
being ideal for interaction with the target. For rac-5a, featuring
an aldehyde function in one of the aromatic 4-positions of rac-
SNAP-5114 (rac-2), a pIC50 of 5.77�0.04 was determined
(Table 5, entry 2), which places the potency of compound rac-
5a nominally above that of rac-SNAP-5114 (rac-2) despite the
oxygen atom being placed one bond further away from the
aromatic moiety. 5b, which has one of the methoxy groups of
rac-2 replaced by the larger, but similar polar acetyl moiety (5b:
clog D=2.00), exhibits only a slightly decreased inhibitory
potency compared to the parent compound, with its pIC50 value
amounting to 5.43�0.04 (Table 5, entry 6). On the other hand,
the introduction of a hydroxymethylene group, leading to the
distinctly more polar compound 5m (clog D=1.71), is accom-
panied by a reduction of the pIC50 value from 5.64�0.05 for
rac-SNAP-5114 to 4.90, which equates to a potency loss of ~0.75
log units (Table 5, entry 28). Interestingly, an equivalent pIC50 of
4.86 was determined for 5e (Table 5, entry 12), which has one
of the three aromatic 4-positions of rac-2 occupied by a
carboxylic acid moiety. This finding is astonishing as the
carboxyl group is significantly more polar than the correspond-
ing alcohol moiety present in 5m, with the respective clog D
value amounting to   1.40 under physiological conditions.
By contrast, the inhibitory potency of 5 j, featuring a
carboxamide moiety in this position, is strongly reduced
(pIC50<4.0, remaining [
3H]GABA at 100 μM=65.2%, Table 5,
entry 22), irrespective of the fact that this group is of similar
size as the carboxylic acid found in 5e while conveying a less
pronounced increase in polarity (clog D=1.32). Apparently, no
correlation between polarity and inhibitory potency seems to
exist. 5c, which features a N,N-dimethyl sulfonamide group
(clog D=1.98) in place of one of the methoxy groups of rac-2,
is characterized by an even lower activity; the compound causes
a [3H]GABA uptake reduction to 82.0% at 100 μM, denoting a
pIC50 of well below 4.0 (Table 5, entry 8).
Of the compounds obtained from 12a by reductive
amination and subsequent hydrolysis, 5n, featuring a glycine
partial structure that is connected to the 4-position of one of
the aromatic moieties by a methylene spacer, reduces the [3H]
GABA uptake to 72.2% at 100 μM test compound concentration
(Table 5, entry 30); its analogue derived from β-alanine, 5o,
causes a slightly more pronounced reduction to 56.3% (Table 5,
entry 32). In this context, it is noticeable that the potency of the
free nipecotic acid derivatives 5n and 5o is even lower than
Table 5. continued
Entry Compound R1 R2 R3 R4 X pKi
[a] pIC50
[b]
mGAT1 mGAT2 mGAT3 mGAT4
36 5q OMe OMe OH O 77.0% 80.7 % 77.0 % 61.1 % 4.34
37 5r OMe OMe OH O 97.0% 76.0 % 79.7 % 64.2 % 4.19
38 12s OMe OMe OEt O 84.9% 52.4 % 76.7 % 59.3 % 67.6 %
39 5s OMe OMe OH O 86.5% 48.5 % 51.5 % 4.33 4.13
40 12t OMe OMe OEt O 101.6% 52.3% 73.5% 49.7% 63.9%
41 5t OMe OMe OH O 54.1% 99,5% 4,18 96,0% 50,0%
[a] Results of the MS Binding Assays are given as pKi�SEM. For compounds with low pKi values only one measurement was performed, therefore no SEM can
be reported. Percent values represent remaining specific NO711 binding in presence of 100 μM compound. [b] Results of the [3H]GABA uptake assays are
given as pIC50�SEM. For compounds with low pIC50 values only one measurement was performed, therefore no SEM can be reported. Percent values
represent remaining [3H]GABA uptake in presence of 100 μM compound.
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that of the corresponding esters 12n [pIC50 (mGAT4)=4.18,
Table 5, entry 29] and 12o [pIC50 (mGAT4)=4.66, Table 5,
entry 31]. By contrast, compounds that contain bulky, sterically
hindered amino acid partial structures in the same position,
such as 1-aminocyclopropane-1-carboxylic acid (5p) and 2-
amino-2-methylpropanoic acid (5q), are characterized by a
pIC50 of 4.88 (Table 5, entry 34) and 4.34 (Table 5, entry 36),
respectively. Since these substances retain comparatively more
of the inhibitory activity at mGAT4 of the parent compound,
increased space requirements do evidently not contribute to
the decline in potency in this case. Compound 5s, which
formally results from elongation of the amino acid chain of 5o
by one methylene group, hence exhibiting a γ-aminobutyric
acid subunit, shows slightly higher inhibitory potency with a
pIC50 value of 4.13 compared to its shorter chain analogues
(compare Table 5, entry 39 to entry 30 and 32). Compound 5t,
whose 4-aminobenzoic acid partial structure resembles to some
extent a more rigid homologue of the γ-aminobutyric acid
moiety present in 5s, is characterized by equal inhibitory
potency (remaining [3H]GABA at 100 μM=50.0%, Table 5,
entry 41). Surprisingly, 5r, featuring a lactam structure derived
from the γ-aminobutyric acid substructures present in 5s,
exhibits a similar activity at mGAT4 (pIC50=4.19, Table 5,
entry 37), despite not possessing an ionized functional group in
the aromatic domain and thus having a distinctly higher clog D
value of 1.87 compared to the value of   0.44 calculated for 5s.
In conclusion, the data imply no clear correlation between
the polarity and size of the compound and the inhibitory
potency exerted at mGAT4. Still the fact remains conspicuous
that all test compounds with a free carboxylic acid function of
the nipecotic acid residue possessing a pIC50�5.0 contain a
functional group that can act as hydrogen bond acceptor, but
not as donor, and that is of similar size as the 4-methoxy moiety
in the lipophilic domain it replaces. Furthermore, the clog D
values calculated for these compounds consistently lie in the
range of 2.0–2.4, as is the case with the parent compound rac-2
(clog D=2.32) and the most potent inhibitor synthesized within
the scope of this study, 5a (clog D=2.15). This might turn out
to be beneficial with regard to potential therapeutic applica-
tions, since compounds with log D values between 2 and 5,[36]
or even better with values closer to 2,[37] are thought to possess
the highest propensity for blood-brain barrier (BBB) penetra-
tion.
Since 5a turned out to be the most potent mGAT4 inhibitor
of all racemic compounds tested for this study, its enantiopure
isomers (S)-5a and (R)-5a were synthesized and evaluated for
their biological activities as well. As is the case with the lead
substance SNAP-5114, the (S)-enantiomer of 5a was found to
exhibit a more pronounced inhibitory potency at mGAT4 than
the (R)-enantiomer, with the respective pIC50 values amounting
to 5.89�0.07 for (S)-5a (Table 5, entry 3) and 4.86�0.03 for (R)-
5a (Table 5, entry 4). Hence, (S)-5a constitutes nominally a
more potent mGAT4 inhibitor than the benchmark compound
(S)-2 (pIC50=5.71�0.07, Table 1, entry 3).
Next, we aimed to elucidate whether the biological activity
of 5a is solely attributable to competitive inhibition at the
target, or whether a reaction of the aldehyde function with [3H]
GABA serving as substrate in the [3H]GABA uptake assay might
have affected the outcome of the biological study. Reaction of
[3H]GABA with the aldehyde function of the test compounds
5a, (S)-5a and (R)-5a might lead to depletion of the substrate
of the uptake assay, thus falsifying the outcome of the assay.
Alternatively, a thus formed intermediate might be a potent
inhibitor by itself. To this end the uptake experiment was
repeated using an assay recently developed by our group,[38]
which has GABA replaced by the chemically inert imidazolacetic
acid. Since 5a and its enantiopure isomers (R)-5a and (S)-5a
display similar inhibitory activity when tested under these
conditions as compared to the assay based on [3H]GABA, it
appears reasonable to assume that possible reactions of the
aldehyde function of 5a with the substrate does not, or at least
not crucially, contribute to the biological effects observed for
this compound.
Due to the presence of an aldehyde function in 5a, it had to
be considered whether the compound 5a might form covalent
bonds with the target. In order to explore this possibility, we
examined 5a in comparison with (S)-SNAP-5114 [(S)-2] for
inhibition of GABA uptake at mGAT4 by varying the time period
used for preincubation (i. e. the period in which target and test
compound are in contact, before the substrate is added). We
studied preincubation times of 10, 25 min (which is our
standard preincubation time in our GABA uptake assays) as well
as 60 min and compared the inhibitory potencies of 5a and (S)-
SNAP-5114 [(S)-2] under these conditions. The determined
pIC50-values revealed a very slight enhancement of inhibitory
potencies with increasing preincubation times almost exactly to
the same extent for both compounds (see supporting informa-
tion, Table 1). As 5a and (S)-SNAP-5114 [(S)-2] behaved identical
in this respect, the basic way of interaction of both compounds
with mGAT4 seems to be similar, arguing against a covalent
interaction of 5a with mGAT4.
Of the rac-SNAP-5114 (rac-2) analogues that have an entire
4-methoxyphenyl residue replaced by a polar moiety, 5d,
possessing an imidazo[1,2-α]pyridine subunit instead of the
aforementioned 4-methoxyphenyl rest, displays a pIC50 of 4.58
(Table 5, entry 10). As compared to the potency of rac-2a at
mGAT4 (pIC50=5.64�0.05) this equates to a distinct, but still
moderate reduction of inhibitory potency of about one log unit.
However, the introduction of a small, polar functional group in
place of one of the 4-methoxyphenyl residues is associated
with a drastic loss of activity at mGAT4. For example, the
compound featuring a carboxylic acid function in this position,
5k, is devoid of almost any inhibitory activity at mGAT4,
reducing the [3H]GABA uptake to only 96.5% at 100 μM
(Table 5, entry 24). By comparison, 5e, which also features a
carboxyl group, albeit located on one of the aromatic residues
of the lipophilic domain of rac-2 supplanting a 4-methoxy
group, conserves significantly more of the inhibitory potency of
the parent compound [pIC50(mGAT4)=4.86, Table 5, entry 12].
The same phenomenon is observed for 5 l, that formally results
from the replacement of one of the 4-methoxyphenyl groups of
rac-2 with a hydroxy moiety, in combination with a simulta-
neous exchange of the ether oxygen of the spacer by a
methylene group to warrant chemical stability. The compound
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reduces the [3H]GABA uptake to 92.0% at 100 μM (Table 5,
entry 26). Compound 5m on the other hand, which also
contains a hydroxy function, but retains triaryl pattern of the
parent compound by substituting one of the three methoxy
groups with a hydroxymethylene moiety, still possesses a pIC50
of 4.90 (Table 5, entry 28). These results suggest that decreasing
size and steric demand of the lipophilic domain is accompanied
by a pronounced decline in biological activity at mGAT4. The
three aromatic moieties on the quaternary carbon atom can
therefore be regarded as essential for high inhibitory potency at
mGAT4 of these compounds, and variations, e.g. in order to
alter the polarity of a compound, should only be implemented
by modification of the substituents, but not by replacement of
one of these aromatic moieties in favour of a smaller functional
group.
Next, we aimed to study how the number of aryl moieties in
the lipophilic domain, which are modified with regard to their
substituents, affects the inhibitory potency. To that end, an
array of rac-SNAP-5514 analogues was synthesized that had
one, two, or all three of the methoxy groups replaced by
methoxymethylene moieties. While the introduction of one
methoxymethylene group caused only a minor decrease in
inhibitory potency to a pIC50 of 5.42 (5f, Table 5, entry 14) as
compared to the reference compound rac-2 (pIC50=5.64�0.05,
Table 1, entry 2), the loss of activity became increasingly more
pronounced with each further methoxymethylene group (5h,
mGAT4: pIC50=4.77, Table 5, entry 18; 5 i, mGAT4: remaining
[3H]GABA at 100 μM=76.1%, Table 5, entry 20). These findings
support the notion that the biological system can tolerate an
inapt substituent on one of the aryl groups relatively well as
long as the other two 4-methoxy moieties of the lipophilic
domain remain unchanged and thus are still available for
interactions with the target. However, substitution of further
methoxy moieties will result in an exceeding decline of
inhibitory potency at mGAT4.
Also the nipecotic acid ester derivatives 12 that have been
synthesized in this study were evaluated for their inhibitory
potencies at all four GAT subtypes. With regard to mGAT4
inhibition, most nipecotic acid esters 12 display distinctly lower
potencies at this transporter subtype than their nipecotic acid
analogues 5, signifying the importance of the free nipecotic
acid partial structure for mGAT4 inhibition. Only in case of the
nipecotic acids 5j–5 l which exert very low inhibitory potencies
at mGAT4 (pIC50<4.0), the inhibitory potencies of the free acids
were lower than that of the corresponding esters 12 j–12 l, the
differences being, however, marginal. However, carboxylic acid
ester 12k cannot be directly compared to nipecotic acid 5k, as
the latter possesses a carboxy function instead of a methoxy
carbonyl moiety attached to one of the aryl residues of the
lipophilic domain.
Regarding the effects at other GAT subtypes, inhibition of
mGAT1 is the pharmacologically most relevant due to its high
abundance in the mammalian CNS. Of the compounds
presented in this study, none of the carboxylic acid analogues
of rac-SNAP-5114 5 show a reasonable inhibitory potency at
mGAT1, i. e. pIC50 values�4, which is also true for the ester
analogues 12 with two exceptions. Thus, for 12d, that has one
of the three 4-methoxyphenyl groups (of rac-2) substituted by
an imidazo[1,2-a]pyridine-7-yl moiety, and 12o, featuring a β-
alanine ethyl ester partial structure which is linked to one of the
three aromatic residues in the 4-position by a methylene spacer,
pIC50 values of 4.39 and 4.59 were found (12d, Table 5, entry 9,
and 12o, Table 5, entry 31). All other compounds lie below that
mark, i. e. a pIC50=4.0, and can thus be regarded as less potent
mGAT1 inhibitors than rac-2, which has a pIC50 of 4.08 (2,
Table 1, entry 2). Hence, contrary to what applies to the potency
at mGAT4, transforming the ester function of 12 into a free acid
moiety exerts little to no influence on inhibitory potency at
mGAT1, the latter usually amounting to pIC50 values of below
4.0 for both compound classes.
The compounds synthesized and tested for this study were
generally found to be weak binders at mGAT1, which correlates
well with the uniformly low inhibitory potencies at this GABA
transporter subtype. In that context, only the rac-SNAP-5114
analogues possessing a formyl [(5a), (R)-5a], acetyl (5b), or
nitrile function (5g) in the lipophilic domain or in which a 4-
methoxyphenyl residue has been replaced by an imidazo[1,2-a]
pyridine-7-yl moiety (5d) or an hydroxy function (5 l) differ by
displaying moderate pKi values >4.0. In detail, the values
determined for these compounds were 4.50�0.06 (5a, Table 5,
entry 2), 4.91�0.09 [(R)-5a, Table 5, entry 4], 4.51�0.03 (5b,
Table 5, entry 6), 4.40�0.01 (5g, Table 5, entry 16), 4.03 (5d,
Table 5, entry 10) and 4.49 (5 l, Table 5, entry 26), respectively.
Furthermore, none of the free nipecotic acids 5 reduced [3H]
GABA below 50% at a concentration of 100 μM when tested at
mGAT2, which corresponds to pIC50 values <4.0, except for 5t
(pIC50=4.18, Table 5, entry 41). Nevertheless, some of the ester
precursors 12 exceeded this mark, the most potent among
these being the imidazo[1,2-a]pyridine derivative 12d with a
pIC50 of 4.88 (Table 5, entry 9). Likewise, the ester derivatives of
the compounds that feature in the lipophilic domain a formyl
(12a, Table 5, entry 1, pIC50=4.57), a methoxymethyl (12h,
Table 5, entry 17, pIC50=4.30) or an amino acid residue (12n,
Table 5, entry 29, pIC50=4.29; 12o, Table 5, entry 31, pIC50=
4.72) display pIC50 values�4.00 at this transporter subtype.
Serving as lead structure of this study, rac-SNAP-5114 (rac-2)
possesses a comparatively high pIC50 value at mGAT3 of 4.96
(Table 1, entry 2); as a consequence, its desired mGAT4
selectivity is quite poor with regard to this GAT subtype. The
modifications of the rac-2 structure that were undertaken for
the purpose of this study resulted in compounds with lower
activity at mGAT3, 5a being the only exception (pIC50=4.98�
0.08, Table 5, entry 2). This is of particular importance for those
compounds that show relatively high inhibitory potency at
mGAT4 and are thus of interest as pharmacological tools. In
case of 5b and 5f, which comprise an acetyl group and a
methoxymethylene group in the lipophilic domain, the inhib-
itory potency at mGAT4 is moderately reduced to pIC50 values
of 5.43�0.04 (5b, Table 5, entry 6) and 5.42�0.10 (5f, Table 5,
entry 14), respectively. However, the potency loss at mGAT3
caused by these structural modifications is slightly more
pronounced, with a pIC50 value of 4.24�0.02 determined for
5b (Table 5, entry 6) and 4.51�0.04 for 5f (Table 5, entry 14).
Accordingly, these compounds display considerably higher
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mGAT4 selectivity than rac-2, albeit at the cost of some
inhibitory potency.
As compared to the enantiopure benchmark inhibitor (S)-2
(Table 1, entry 3), the most potent compound synthesized for
this study, (S)-5a, displays almost identical subtype selectivity
(Table 5, entry 3). In particular, the pIC50 values amount to
5.16�0.05 at mGAT3 [(S)-2: 5.29�0.04] and 4.14�0.00 at
mGAT1 [(S)-2: 4.07�0.09]. At mGAT2 both compounds exert
only weak inhibitory effects, reducing the [3H]GABA uptake to
72.6% [(S)-5a] and 56% [(S)-2], respectively. Hence, (S)-5a can
be considered a viable alternative to (S)-2 as a pharmacological
tool.
Conclusions
In order to gain insight into the structure activity relationship of
mGAT4 inhibitors, analogues of rac-SNAP-5114 were synthe-
sized that differ from the parent compound by having one or
more of the 4-methoxy groups attached to the lipophilic
domain, or a complete 4-methoxyphenyl group, replaced by a
moiety with higher polarity. These modifications might increase
interactions between the inhibitor and polar regions of binding
site, and hence improve binding affinity, inhibitory potency,
and selectivity.
The test compounds were accessible through conversion of
tertiary alcohols featuring the respective functional groups or
appropriate precursors into the corresponding chlorides, fol-
lowed by etherification with ethyl N-(2-hydroxyethyl)nipecoti-
nate. The obtained N-substituted nipecotic acid esters were
either directly hydrolyzed at this stage, or functional group
interconversions were performed beforehand, including the
introduction of various amino acid partial structures via
reductive amination.
The biological evaluation of the obtained N-substituted
nipecotic acids revealed no direct correlation between the
polarity of the newly introduced group and the biological
activity of the resulting compound. However, compounds with
clog D values of 2.0–2.4 consistently exert the highest inhibitory
potencies. In this context, we found (S)-1-{2-[(4-formylphenyl)bis
(4-methoxyphenyl)methoxy]-ethyl}piperidine-3-carboxylic acid
[(S)-5a], that has one of the three methoxy groups of the parent
substance substituted by a formyl moiety, to be the most
potent test compound synthesized in this study. Being charac-
terized by a pIC50 value of 5.89�0.07 at mGAT4, it even exhibits
slightly higher inhibitory potency than the benchmark sub-
stance (S)-SNAP-5114, while showing comparable subtype
selectivity. Furthermore, the racemic SNAP-5114 analogues
comprising in the lipophilic domain an acetyl and an meth-
oxymethylene substituent, respectively, were found to be
slightly less potent mGAT4 inhibitors than the parent com-
pound, but somewhat more subtype selective, especially at
mGAT3.
Also, it has been demonstrated that rac-SNAP-5114 ana-
logues that have one of the aromatic moieties in the lipophilic
domain replaced by a small, non-aromatic moiety show a
distinct deprivation of inhibitory potency. This finding indicates
the essentiality of the triaryl structure in the lipophilic domain
for the biological activity of mGAT4 inhibitors. Finally, we
determined how the substitution of several methoxy groups in
the lipophilic domain of rac-SNAP-5114 impacts the inhibitory
potency of the resulting compounds using the example of the
methoxymethylene group. As the results of the biological
evaluation suggest, mGAT4 can tolerate one inapt substituent
reasonably well. However, the replacement of additional meth-
oxy groups will result in an exceeding decline of inhibitory
potency.
These findings are expected to be beneficial for future
developments of more potent mGAT4 inhibitors since they
reveal essential structure activity relationships with regard to
size, polarity, and electronic effects of the substituents in the
lipophilic domain.
Experimental Section
Chemistry
Moisture-sensitive reactions were carried out in oven-dried glass-
ware under inert gas atmosphere. Commercially available starting
materials were used without further purification. Dry acetonitrile
(MeCN) was purchased from VWR (HiPerSolv Chromanonorm, water
content >30 ppm) and tetrahydrofuran (THF) was freshly distilled
from sodium benzophenone ketyl. All other solvents were distilled
prior to use. Microwave reactions were carried out with CEM
Discover® SP Microwave Synthesizer (model no. 909 155). Flash
column chromatography was performed according to Still et al.[39]
using Merck silica gel 60 (mesh 0.040–0.063 mm) as stationary
phase. Thin-layer chromatography (TLC) was carried out on Merck
silica gel 60 F254 sheets.
1H and 13C NMR spectra were, unless stated
otherwise, recorded at room temperature with J NMR-GX (JEOL 400
or 500 MHz) or Bruker BioSpin Avance III HD (400 or 500 MHz) and
integrated with the NMR software MestReNova. IR samples were
measured as KBr pellets or film with Perkin-Elmer FT-IR 1600. HRMS
data were obtained with JMS-GCmate II (EI, Jeol) or Thermo
Finnigan LTQ FT Ultra (ESI, Thermo Finnigan).
General procedure for the synthesis of trityl alcohols by Grignard
reaction (GP1): Magnesium turnings were scraped with a glass rod
and suspended in dry THF. The appropriate aryl halide or a solution
thereof in THF was added portion wise. After completion of the
Grignard reagent formation a solution of the electrophile in THF
was added dropwise to the solution. The mixture was stirred for the
prescribed time and temperature, quenched with saturated
ammonium chloride (NH4Cl) solution, diluted with water and
extracted thrice with dichloromethane (CH2Cl2). The combined
organic phases were dried over magnesium sulfate (MgSO4), filtered
and reduced in vacuum.
General procedure for the synthesis of trityl alcohols by lithiation of
an aryl halide and subsequent reaction with 4,4’-dimeth-
oxybenzophenone (GP2): tert-Butyllithium solution (1.7 M in
pentane, 2.0 eq.) was added dropwise to a solution of the aryl
halide (1.0 eq.) in THF at   78 °C. After 2 h a solution of 4,4’-
dimethoxybenzophenone (1.0 eq) in THF was added. The mixture
was allowed to slowly warm up to room temperature overnight,
quenched with water and extracted thrice with CH2Cl2. The
combined organic phases were dried over MgSO4, filtered and
reduced in vacuum.
General procedure for the etherification of tertiary alcohols (GP3): The
tertiary alcohol (1.0 eq) was charged with a catalytic amount of
ChemMedChem
Full Papers
doi.org/10.1002/cmdc.201900719
766ChemMedChem 2020, 15, 756–771 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Dienstag, 28.04.2020
2009 / 161993 [S. 766/771] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
DMF. Acetyl chloride was added and the reaction mixture was
stirred at room temperature for 24 hours, reduced in vacuum and
dried under high vacuum. The oily or solid residue was solved in
dry MeCN. Racemic, (R)- or (S)-ethyl 1-(hydroxyalkyl)nipecotinate
(1.1 eq) and oven-dried potassium carbonate (K2CO3, 2.5 eq) were
added. After stirring 16 hours at room temperature, the mixture
was filtered and reduced in vacuum.
General procedure for the hydrolysis of the ethyl ester function (GP4):
The ester (1.0 eq) was dissolved in MeOH. Double distilled water
and barium hydroxide octahydrate (2.0–4.0 eq) were added and the
mixture was stirred at room temperature until TLC indicated
complete consumption of the ester. Carbon dioxide was passed
through the solution until no further precipitate formed. The
suspension was diluted with MeOH (1 :1), filtered through a paper
filter and reduced in vacuum. If necessary, the crude acid was
purified by flash column chromatography. The solid residue was
solved in MeOH (1.0 mL), filtered through a syringe filter (Perfect-
Flow®, WICOM Germany GmbH, PTFE, 0.2 μM), diluted with double
distilled water (4.0 mL) and lyophilized.
General procedure for reductive amination I (GP5): The appropriate
amino acid ester hydrochloride (2.0 eq) and sodium triacetoxybor-
ohydride (1.4 eq) were added to a solution of aldehyde 3a (1.0 eq)
in CH2Cl2. The reaction mixture was stirred at room temperature
until TLC indicated complete consumption of the aldehyde,
quenched with saturated sodium carbonate (Na2CO3) solution and
extracted thrice with CH2Cl2. The combined organic phases were
dried over MgSO4, filtered and reduced in vacuum.
General procedure for reductive amination II (GP6): The appropriate
amino acid (2.0 eq) and sodium cyanoborohydride (1.4 eq) were
added to a solution of aldehyde 3a (1.0 eq) in MeOH. The reaction
mixture was stirred at room temperature until TLC indicated
complete consumption of the aldehyde and reduced in vacuum.
rac-1-{2-[(4-Formylphenyl)bis(4-methoxyphenyl)methoxy]ethyl}
piper-idine-3-carboxylic acid (5a): GP4 was followed using 12a
(101 mg, 0.190 mmol), barium hydroxide octahydrate (241 mg,
0.764 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent MeOH).
Amorphous colourless solid (85 mg, 89%).
(S)-1-{2-[(4-Formylphenyl)bis(4-methoxyphenyl)methoxy]ethyl}
piper-idine-3-carboxylic acid [(S)-5a]: GP4 was followed using (S)-
12a (38 mg, 0.071 mmol), barium hydroxide octahydrate (90 mg,
0.28 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent MeOH).
Amorphous colourless solid (34 mg, 93%).
(R-1-{2-[(4-Formylphenyl)bis(4-methoxyphenyl)methoxy]ethyl}pi-
peridine-3-carboxylic acid [(R)-5a]: GP4 was followed using (R)-
12a (37 mg, 0.070 mmol), barium hydroxide octahydrate (89 mg,
0.28 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent MeOH).
Amorphous colourless solid (32.5 mg, 92%).
rac-1-{2-[(4-Acetylphenyl)bis(4-methoxyphenyl)methoxy]ethyl}pi-
peridine-3-carboxylic acid (5b): GP4 was followed using 12b
(87 mg, 0.16 mmol), barium hydroxide octahydrate (197 mg,
0.62 mmol), MeOH/H2O 4 :1 (3.5 mL). The crude compound was
purified by flash column chromatography on silica (eluent MeOH).
Amorphous colourless solid (69 mg, 86%).
rac-1-(2-{[4-(N,N-dimethylsulfamoyl)phenyl]bis[4-meth-
oxyphenyl]-methoxy}ethyl)piperidine-3-carboxylic acid (5c): GP4
was followed using 12c (66 mg, 0.11 mmol), barium hydroxide
octahydrate (137 mg, 0.434 mmol), MeOH/H2O 4 :1 (3.0 mL). The
crude compound was purified by flash column chromatography on
silica (eluent MeOH). Amorphous colourless solid (55 mg, 88%).
rac-1-(2-{Imidazo[1,2-a]pyridin-6-ylbis(4-methoxyphenyl)meth-
oxy}-ethyl)piperidine-3-carboxylic acid (5d): GP4 was followed
using 12d (78 mg, 0.14 mmol), barium hydroxide octahydrate
(170 mg, 0.54 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude com-
pound was purified by flash column chromatography on silica
(eluent MeOH/CH2Cl2 1 :1). Amorphous colourless solid (59 mg,
80%).
rac-1-{2-[(4-Carboxyphenyl)bis(4-methoxyphenyl)methoxy]ethyl}
piper-idine-3-carboxylic acid (5e): GP4 was followed using 12e
(200 mg, 0.350 mmol), barium hydroxide octahydrate (222 mg,
0.704 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent MeOH).
Amorphous colourless solid (110 mg, 61%).
rac-1-(2-{[4-(Methoxymethyl)phenyl]bis[4-methoxyphenyl]meth-
oxy}-ethyl)piperidine-3-carboxylic acid (5 f): GP4 was followed
using 12f (72 mg, 0.13 mmol), barium hydroxide octahydrate
(83 mg, 0.26 mmol), MeOH/H2O 4 :1 (12.0 mL). The crude com-
pound was purified by flash column chromatography on silica
(eluent MeOH). Amorphous colourless solid (56 mg, 81%).
rac-1-{2-[(4-Cyanophenyl)bis(4-methoxyphenyl)methoxy]ethyl}pi-
peridine-3-carboxylic acid (5g): GP4 was followed using 12g
(48 mg, 0.090 mmol), barium hydroxide octahydrate (57 mg,
0.18 mmol), MeOH/H2O 4 :1 (2.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent MeOH).
Amorphous colourless solid (39 mg, 86%).
rac-1-(2-{Bis[4-(methoxymethyl)phenyl][4-methoxyphenyl]meth-
oxy}-ethyl)piperidine-3-carboxylic acid (5h): GP4 was followed
using 12h (56 mg, 0.10 mmol), barium hydroxide octahydrate
(127 mg, 0.403 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude com-
pound was purified by flash column chromatography on silica
(eluent MeOH). Amorphous colourless solid (51 mg, 94%).
rac-1-(2-{Tris[4-(methoxymethyl)phenyl]methoxy}ethyl)piperi-
dine-3-carboxylic acid (5 i): GP4 was followed using 12 i (61 mg,
0.11 mmol), barium hydroxide octahydrate (75 mg, 0.44 mmol),
MeOH/H2O 4 :1 (5.0 mL). The crude compound was purified by flash
column chromatography on silica (eluent MeOH). Amorphous
colourless solid (52 mg, 90%).
rac-1-{2-[(4-Carbamoylphenyl)bis(4-methoxyphenyl)methoxy]
ethyl}-piperidine-3-carboxylic acid (5 j): GP4 was followed using
12 j (63 mg, 0.12 mmol), barium hydroxide octahydrate (146 mg,
0.46 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent MeOH).
Amorphous colourless solid (52 mg, 87%).
rac-1-{2-[Carboxybis(4-methoxyphenyl)methoxy]ethyl}piperidine-
3-carboxylic acid (5k): GP4 was followed using 12k (370 mg,
0.760 mmol), barium hydroxide octahydrate (481 mg, 1.52 mmol),
MeOH/H2O 4 :1 (5.0 mL). The crude compound was purified by flash
column chromatography on silica (eluent MeOH). Amorphous
colourless solid (327 mg, 97%).
rac-1-[4-Hydroxy-4,4-bis(4-methoxyphenyl)butyl]piperidine-3-car-
boxylic acid (5 l): GP4 was followed using 12 l (103 mg,
0.230 mmol), barium hydroxide octahydrate (148 mg, 0.469 mmol),
MeOH/H2O 4 :1 (3.6 mL). The crude compound was purified by flash
column chromatography on silica (eluent MeOH). Amorphous
colourless solid (81 mg, 84%).
rac-1-(2-{[4-(Hydroxymethyl)phenyl]bis[4-methoxyphenyl]meth-
oxy}-ethyl)piperidine-3-carboxylic acid (5m): GP4 was followed
using 12m (58 mg, 0.11 mmol), barium hydroxide octahydrate
(69 mg, 0.22 mmol), MeOH/H2O 4 :1 (3.0 mL). The crude compound
was purified by flash column chromatography on silica (eluent
MeOH). Amorphous colourless solid (38 mg, 69%).
ChemMedChem
Full Papers
doi.org/10.1002/cmdc.201900719
767ChemMedChem 2020, 15, 756–771 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Dienstag, 28.04.2020
2009 / 161993 [S. 767/771] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
rac-1-{2-[(4-{[(Carboxymethyl)amino]methyl}phenyl)bis(4-meth-
oxy-phenyl)methoxy]ethyl}piperidine-3-carboxylic acid (5n): GP4
was followed using 12n (35 mg, 0.060 mmol), barium hydroxide
octahydrate (37 mg, 0.12 mmol), MeOH/H2O 4 :1 (5.0 mL). The crude
compound was purified by flash column chromatography on silica
(eluent MeOH). Amorphous colourless solid (29 mg, 65%).
rac-1-{2-[(4-{[(2-Carboxyethyl)amino]methyl}phenyl)bis(4-meth-
oxy-phenyl)methoxy]ethyl}piperidine-3-carboxylic acid (5o): GP4
was followed using 12o (83 mg, 0.13 mmol), barium hydroxide
octahydrate (171 mg, 0.542 mmol), MeOH/H2O 4 :1 (5.0 mL). The
crude compound was purified by flash column chromatography on
silica (eluent MeOH). Amorphous colourless solid (57 mg, 74%).
rac-1-{2-[(4-{[(1-Carboxycyclopropyl)amino]methyl}phenyl)bis(4-
methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid (5p):
GP4 was followed using 12p (51 mg, 0.079 mmol), barium
hydroxide octahydrate (100 mg, 0.317 mmol), MeOH/H2O 4 :1
(6.0 mL). The crude compound was purified by flash column
chromatography on silica (eluent MeOH). Amorphous colourless
solid (50 mg, 82%).
rac-1-{2-[(4-{[(2-Carboxypropan-2-yl)amino]methyl}phenyl)bis(4-
methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid (5q):
GP4 was followed using 12q (35 mg, 0.054 mmol), barium
hydroxide octahydrate (136 mg, 0.431 mmol), MeOH/H2O 4 :1
(5.0 mL). The crude compound was purified by flash column
chromatography on silica (eluent MeOH). Amorphous colourless
solid (29.3 mg, 92%).
rac-1-[2-(Bis{4-methoxyphenyl}{4-[(2-oxopyrrolidin-1-yl)methyl]
phenyl}-methoxy)ethyl]piperidine-3-carboxylic acid (5 r): GP5 was
followed using 12a (173 mg, 0.330 mmol), ethyl 4-aminobutanoate
hydrochloride (109 mg, 0.650 mmol), sodium triacetoxyborohydride
(155 mg, 0.730 mmol), CH2Cl2 (2.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent ethyl
acetate+5% triethylamine), yielding 107 mg of a mixture of rac-
ethyl 1-[2-(bis{4-methoxyphenyl}{4-[(2-oxopyrrolidin-1-yl)methyl]
phenyl}-methoxy)ethyl]piperidine-3-carboxylate and rac-ethyl 1-{2-
[(4-{[(4-methoxy-4-oxobutyl)amino]methyl}phenyl)bis(4-meth-
oxyphenyl)methoxy]ethyl}piperidine-3-carboxylate. 84 mg thereof
were subjected to GP4 using barium hydroxide octahydrate
(178 mg, 0.564 mmol), MeOH/H2O 4 :1 (3.5 mL). The crude com-
pound was purified by flash column chromatography on silica
(eluent MeOH). Amorphous colourless solid (69 mg, 47% over both
steps).
rac-1-{2-[(4-{[(3-Carboxypropyl)amino]methyl}phenyl)bis(4-meth-
oxy-phenyl)methoxy]ethyl}piperidine-3-carboxylic acid (5s): GP4
was followed using 12s (50 mg, 0.081 mmol), barium hydroxide
octahydrate (103 mg, 0.326 mmol), MeOH/H2O 4 :1 (5.0 mL). Amor-
phous colourless solid (40 mg, 84%).
rac-1-{2-[(4-{[(4-Carboxyphenyl)amino]methyl}phenyl)bis(4-meth-
oxy-phenyl)methoxy]ethyl}piperidine-3-carboxylic acid (5 t): 12t
(37.2 mg, 0.057 mmol) was dissolved in THF (1.5 mL) and H2O
(1.5 mL) and barium hydroxide octahydrate (38.4 mg, 4.0 eq) were
added. The mixture was stirred at room temperature until TLC
indicated complete consumption of 12t. Carbon dioxide was
passed through the solution until no further precipitate formed.
The suspension was filtered through a syringe filter (Perfect-Flow®,
WICOM Germany GmbH, PTFE, 0.2 μM) and lyophilized. Amorphous
colourless solid (34.0 mg, 96%).
[4-(Dimethoxymethyl)phenyl]bis(4-methoxyphenyl)methanol
(8a): GP2 was followed using tert-butyllithium solution (1.7 M in
pentane, 1.2 mL, 2.04 mmol), 1-bromo-4-(dimethoxymethyl)
benzene 9a (235 mg, 1.02 mmol), THF (3.0 mL). Addition of 4,4’-
dimethoxybenzophenone 10a (245 mg, 1.00 mmol) in THF (5.0 mL).
The crude compound was purified by flash column chromatog-
raphy on silica (eluent pentane/Et2O 7 :3). Colourless oil (393 mg,
99%).
Bis(4-methoxyphenyl)[4-(2-methyl-1,3-dioxan-2-yl)phenyl]metha-
nol (8b): GP2 was followed using tert-butyllithium solution (1.7 M
in pentane, 3.3 mL, 5.6 mmol), 2-(4-bromophenyl)-2-methyl-1,3-
dioxane 9b (713 mg, 2.77 mmol), THF (12.0 mL). Addition of 4,4’-
dimethoxybenzophenone 10a (700 mg, 2.83 mmol) in THF
(12.0 mL). The crude compound was purified by flash column
chromatography on silica (eluent pentane/Et2O 8 :2). Colourless
semi-solid (1.02 g, 87%).
4-[Hydroxybis(4-methoxyphenyl)methyl]-N,N-dimeth-
ylbenzenesulfon-amide (8c): GP2 was followed using tert-butyl-
lithium solution (1.7 M in pentane, 2.7 mL, 4.6 mmol), 9c (561 mg,
2.27 mmol), THF (30.0 mL). Addition of 4,4’- dimeth-
oxybenzophenone 10a (561 mg, 2.27 mmol) in THF (12.0 mL). The
crude compound was precipitated from isohexane/THF. Amorphous
colourless solid (514 mg, 53%).
Imidazo[1,2-a]pyridin-6-ylbis(4-methoxyphenyl)methanol (8d): N-
butyl-lithium solution (2.4 M in hexane, 1.0 mL, 2.4 mmol) was
added dropwise to a suspension of 6-bromoimidazo[1,2-a]pyridine
9d (483 mg, 2.40 mmol) in Et2O (24.0 mL) at   78 °C. After 30 min a
suspension of 4,4’-dimethoxybenzophenone 10a (494 mg,
2.0 mmol) in Et2O was added. The mixture was stirred 1 h at   78 °C,
warmed to room temperature, quenched with water (20.0 mL) and
extracted thrice with ethyl acetate (20.0 mL). The combined organic
phases were washed with saturated Na2CO3 solution, dried over
MgSO4, filtered and reduced in vacuum. The crude compound was
purified by flash column chromatography on silica (eluent CH2Cl2+
2% MeOH). Amorphous slightly yellowish solid (400 mg, 56%).
Ethyl 4-[hydroxybis(4-methoxyphenyl)methyl]benzoate (8e):
Isopropyl-magnesium chloride (2.0 M solution in THF, 1.0 mL,
2.0 mmol) was added dropwise to a solution of ethyl 4-iodoben-
zoate 9e (547 mg, 2.02 mmol) in THF (5.0 mL) at   20 °C. The
mixture was stirred for 1.5 h and a solution of 4,4’-dimeth-
oxybenzophenone 10a (445 mg, 1.80 mmol) in THF (5.0 mL) was
slowly added via syringe. Stirring was continued at 0 °C over night.
The reaction mixture was allowed to slowly warm up to room
temperature, quenched with saturated NH4Cl solution and ex-
tracted thrice with CH2Cl2. The combined organic phases were dried
over MgSO4, filtered and reduced in vacuum. The resulting crude
compound was purified by flash column chromatography on silica
(eluent pentane/Et2O 8 :2). Colourless semi-solid (328 mg, 77%).
[4-(Methoxymethyl)phenyl]bis(4-methoxyphenyl)methanol (8 f):
GP2 was followed using tert-butyllithium solution (1.7 M in pentane,
5.0 mL, 8.50 mmol), 1-bromo-4-(methoxymethyl)benzene 9f
(848 mg, 4.22 mmol), THF (24.0 mL). Addition of 4,4’-dimeth-
oxybenzophenone 10a (1.05 g, 4.25 mmol) in THF (12.0 mL). The
crude compound was purified by flash column chromatography on
silica (eluent pentane/Et2O 7 :3). Amorphous colourless solid (1.42 g,
92%).
4-[Hydroxybis(4-methoxyphenyl)methyl]benzonitrile (8g): GP1
was followed using a Grignard reagent prepared from 4-bromoani-
sol 9g (1.72 g, 9.01 mmol) and magnesium (219 mg, 9.01 mmol) in
THF (20.0 mL). A solution of 4-cyanobenzoyl chloride 10c (736 mg,
4.40 mmol) in THF (8.0 mL) was added dropwise at 0 °C. The
reaction mixture was stirred 2 h at 0 °C and 30 min at 25 °C. The
crude compound was purified by flash column chromatography on
silica (eluent pentane/Et2O 6 :4). Amorphous colourless solid (1.42 g,
94%).
Bis[4-(methoxymethyl)phenyl](4-methoxyphenyl)methanol (8h):
GP1 was followed using a Grignard reagent prepared from 1-
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bromo-4-(methoxymethyl)benzene 9 f (745 mg, 3.70 mmol) and
magnesium (90 mg, 3.7 mmol) in THF (6.0 mL). A solution of methyl
4-methoxybenzoate (560 mg, 3.30 mmol) in THF (6.0 mL) was
added dropwise. The reaction mixture was stirred at room temper-
ature for 16 h and refluxed 90 min. The crude compound was
purified by flash column chromatography on silica (eluent pentane/
Et2O 6 :4). Pale yellowish oil (492 mg, 70%).
Tris[4-(methoxymethyl)phenyl]methanol (8 i): GP1 was followed
using a Grignard reagent prepared from 1-bromo-4-(methoxymeth-
yl)benzene 9f (1.41 g, 7.00 mmol) and magnesium (170 mg,
6.99 mmol) in THF (10.0 mL). Dimethyl carbonate (209 mg,
2.30 mmol) was added dropwise at room temperature. The reaction
mixture was refluxed 90 min, then stirred at room temperature over
night. The crude compound was purified by flash column
chromatography on silica (eluent pentane/Et2O 1 :1). Colourless oil
(771 mg, 85%).
4-[Hydroxybis(4-methoxyphenyl)methyl]benzamide (8 j): A mix-
ture of 4-[hydroxybis(4-methoxyphenyl)methyl]benzonitrile 8g
(171 mg, 0.500 mmol) and potassium tert-butoxide (340 mg,
3.00 mmol) was stirred in tert-butanol (4.0 mL) at 50 °C for 40 h.
Water (25 mL) was added ad the mixture was extracted thrice with
CH2Cl2 (30.0 mL). The combined organic phases were dried over
MgSO4 and reduced in vacuum. The crude compound was purified
flash column chromatography on silica (eluent isohexane/ethyl
acetate 3 :7). Amorphous colourless solid (173 mg, 96%).
Methyl 2-hydroxy-2,2-bis(4-methoxyphenyl)acetate (8k): A mix-
ture of 4,4’-dimethoxybenzilic acid (2.78 g, 9.64 mmol) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU, 2.65 g, 17.4 mmol) in MeCN
(4.5 mL) was cooled to 0 °C and iodomethane (5.02 g, 35.0 mmol)
was added. The ice bath was removed and stirring was continued
for 48 h at ambient temperature. The reaction mixture was reduced
in vacuum and purified by flash column chromatography on silica
(eluent pentane/Et2O 2 :1 to 1 :1). Amorphous colourless solid
(2.64 g, 91%).
4-Chloro-1,1-bis(4-methoxyphenyl)butan-1-ol (8 l): GP1 was fol-
lowed using a Grignard reagent prepared from 4-bromoanisol
(0.94 g, 4.98 mmol) and magnesium (122 mg, 5.02 mmol) in THF
(12.0 mL). A solution of 4-chloro-1-(4-methoxyphenyl)butan-1-one
(1.06 g, 5.00 mmol) in THF (12.0 mL) was added dropwise at 0 °C.
The reaction mixture was stirred 1 h at ambient temperature. The
crude compound was purified by flash column chromatography on
silica (eluent isohexane/ethyl acetate 9 :1). Colourless oil (1.06 g,
66%).
4-Bromo-N,N-dimethylbenzenesulfonamide (9d): A mixture of 4-
bromobenzenesulfonamide (2.40 g, 10.2 mmol), tetrabutylammo-
nium tetrafluoroborate (329 mg, 1.02 mmol), K2CO3 (5.58 g,
40.4 mmol) and dimethyl sulfate (2.53 g, 20.0 mmol) in MeCN
(15.0 mL) was refluxed for 3 h. After cooling to room temperature
concentrated ammonium hydroxide solution (5.0 mL) was added
and stirring was continued for 16 h. The reaction mixture was
poured into water (20.0 mL) and extracted thrice with CH2Cl2
(30.0 mL). The combined organic phases were dried over MgSO4,
filtered and reduced in vacuum. The crude compound was purified
by flash column chromatography on silica (eluent pentane/Et2O
7 :3). Amorphous colourless solid (2.66 g, 99%).
1-{4-[Hydroxybis(4-methoxyphenyl)methyl]phenyl}ethan-1-one
(11): Concentrated hydrochloric acid (3.0 mL) was added to a
solution of 8b (430 mg, 1.02 mmol) in THF (12.0 mL). The mixture
was refluxed overnight, basified with 2 M NaOH and extracted
thrice with CH2Cl2. The combined organic phases were dried over
MgSO4, filtered and reduced in vacuum. The crude compound was
purified by flash column chromatography on silica (eluent pentane/
Et2O 1 :1). Amorphous colourless solid (345 mg, 93%).
rac-Ethyl 1-{2-[(4-formylphenyl)bis(4-methoxyphenyl)methoxy]
ethyl}-piperidine-3-carboxylate (rac-12a): GP3 was followed using
8a (2.68 g, 6.35 mmol), acetyl chloride (10.0 mL), rac-ethyl 1-(2-
hydroxyethyl)nipecotinate (1.41 g, 6.99 mmol), K2CO3 (2.20 g,
15.9 mmol), acetonitrile (20.0 mL). The crude compound was
purified by two consecutive flash column chromatographic runs on
silica (eluent pentane/Et2O 1 :1+5% triethyl amine; Et2O 100%).
Colourless oil (2.35 g, 70%).
(S)-Ethyl 1-{2-[(4-formylphenyl)bis(4-methoxyphenyl)methoxy]
ethyl}-piperidine-3-carboxylate [(S)-12a]: GP3 was followed using
8a (509 mg, 1.21 mmol), acetyl chloride (3.0 mL), (S)-ethyl 1-(2-
hydroxyethyl)nipecotinate (318 mg, 1.58 mmol), K2CO3 (498 mg,
3.60 mmol), MeCN (5.0 mL). The crude compound was purified by
two consecutive flash column chromatographic runs on silica
(eluent pentane/Et2O 1 :1+5% triethyl amine; Et2O 100%). Colour-
less oil (324 mg, 41%).
(R)-Ethyl 1-{2-[(4-formylphenyl)bis(4-methoxyphenyl)methoxy]
ethyl}-piperidine-3-carboxylate [(S)-12a]: GP3 was followed using
8a (380 mg, 0.900 mmol), acetyl chloride (1.0 mL), (R)-ethyl 1-(2-
hydroxyethyl)nipecotinate (201 mg, 1.00 mmol), K2CO3 (311 mg,
2.25 mmol), MeCN (1.0 mL). The crude compound was purified by
two consecutive flash column chromatographic runs on silica
(eluent pentane/Et2O 1 :1+5% triethyl amine;Et2O 100%). Colour-
less oil (270 mg, 56%).
rac-Ethyl 1-{2-[(4-acetylphenyl)bis(4-methoxyphenyl)methoxy]
ethyl}-piperidine-3-carboxylate (12b): GP3 was followed using 8b
(344 mg, 0.950 mmol), acetyl chloride (3.0 mL), rac-ethyl 1-(2-
hydroxyethyl)nipecotinate (211 mg, 1.05 mmol), K2CO3 (329 mg,
2.38 mmol), MeCN (3.0 mL). The crude compound was purified by
flash column chromatography on silica (eluent pentane/Et2O 6 :4+
5% trimethylamine). Colourless oil (261 mg, 50%).
rac-Ethyl 1-(2-{[4-(N,N-dimethylsulfamoyl)phenyl]bis[4-meth-
oxyphenyl]-methoxy}ethyl)piperidine-3-carboxylate (12c): GP3
was followed using 8c (455 mg, 1.06 mmol), acetyl chloride
(3.0 mL), rac-ethyl 1-(2-hydroxyethyl)nipecotinate (213 mg,
1.06 mmol), K2CO3 (366 mg, 2.65 mmol), MeCN (3.0 mL). The crude
compound was purified by flash column chromatography on silica
(eluent pentane/Et2O 1 :1+5% trimethylamine). Yellowish semi-
solid (411 mg, 64%).
rac-Ethyl 1-(2-{imidazo[1,2-a]pyridin-6-ylbis(4-methoxyphenyl)
methoxy}-ethyl)piperidine-3-carboxylate (12d): GP5 was followed
using 8d (254 mg, 0.710 mmol), acetyl chloride (3.0 mL), rac-ethyl
1-(2-hydroxyethyl)nipecotinate (157 mg, 0.780 mmol), K2CO3
(488 mg, 3.53 mmol), MeCN (5.0 mL). The crude compound was
purified by flash column chromatography on silica (eluent Et2O/
MeOH 9 :1). Yellow semi-solid (160 mg, 48%).
rac-Ethyl 1-(2-{[4-(ethoxycarbonyl)phenyl]bis[4-methoxyphenyl]-
methoxy}ethyl)piperidine-3-carboxylate (12e): GP3 was followed
using 8e (217 mg, 0.550 mmol), acetyl chloride (1.0 mL), rac-ethyl
1-(2-hydroxyethyl)nipecotinate (133 mg, 0.661 mmol), K2CO3
(191 mg, 1.38 mmol), MeCN (2.0 mL). The crude compound was
purified by two consecutive flash column chromatographic runs on
silica (eluent pentane/Et2O 4 :6; pentane/Et2O 8 :2+5% dimeth-
ylethylamine). Colourless semi-solid (173 mg, 54%).
rac- Ethyl 1-(2-{[4-(methoxymethyl)phenyl]bis[4-methoxyphenyl]-
methoxy}ethyl)piperidine-3-carboxylate (12 f): GP3 was followed
using 8f (310 mg, 0.850 mmol), acetyl chloride (5.0 mL), rac-ethyl 1-
(2-hydroxyethyl)nipecotinate (191 mg, 0.949 mmol), K2CO3 (294 mg,
2.13 mmol), MeCN (5.0 mL). The crude compound was purified by
two consecutive flash column chromatographic runs on silica
(eluent Et2O 100%, pentane/Et2O 7 :3+5% triethylamine). Colour-
less oil (207 mg, 44%).
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rac-Ethyl 1-{2-[(4-cyanophenyl)bis(4-methoxyphenyl)methoxy]
ethyl}-piperidine-3-carboxylate (12g): GP3 was followed using 8g
(364 mg, 1.00 mmol), acetyl chloride (1.0 mL), rac-ethyl 1-(2-hydrox-
yethyl)nipecotinate (242 mg, 1.20 mmol), K2CO3 (346 mg,
2.50 mmol), MeCN (5.0 mL). The crude compound was purified by
flash column chromatography on silica (eluent pentane/Et2O/
triethyl amine 4 :4 : 2). Yellowish semi-solid (447 mg, 85%).
rac-Ethyl 1-(2-{bis[4-(methoxymethyl)phenyl][4-methoxyphenyl]-
methoxy}ethyl)piperidine-3-carboxylate (12h): GP3 was followed
using 8h (380 mg, 1.00 mmol), acetyl chloride (3.0 mL), rac-ethyl 1-
(2-hydroxyethyl)nipecotinate (221 mg, 1.10 mmol), K2CO3 (346 mg,
2.5 mmol), MeCN (5.0 mL). The crude compound was purified flash
column chromatography on silica (eluent Et2O). Colourless oil
(260 mg, 46%).
rac-Ethyl 1-(2-{tris[4-(methoxymethyl)phenyl]methoxy}ethyl)pi-
peridine-3-carboxylate (12 i): GP3 was followed using 8 i (243 mg,
0.620 mmol), acetyl chloride (3.0 mL), rac ethyl 1-(2-hydroxyethyl)
nipecotinate (452 mg, 2.25 mmol), K2CO3 (774 mg, 5.60 mmol),
MeCN (5.0 mL). The crude compound was purified by flash column
chromatography on silica (eluent isohexane/Et2O 8 :1 to Et2O
100%). Colourless oil (151 mg, 42%).
rac-Ethyl 1-{2-[(4-carbamoylphenyl)bis(4-methoxyphenyl)meth-
oxy]-ethyl}piperidine-3-carboxylate (12 j): GP3 was followed using
8 j (512 mg, 1.41 mmol), acetyl chloride (5.0 mL), rac-ethyl 1-(2-
hydroxyethyl)nipecotinate (321 mg, 1.55 mmol), K2CO3 (488 mg,
3.53 mmol), MeCN (5.0 mL). The crude compound was purified flash
column chromatography on silica (eluent ethyl acetate+5%
MeOH). Amorphous slightly yellowish solid (375 mg, 49%).
rac-Ethyl 1-{2-[2-methoxy-1,1-bis(4-methoxyphenyl)-2-oxoethoxy]
ethyl}-piperidine-3-carboxylate (12k): GP3 was followed using 8k
(680 mg, 2.24 mmol), acetyl chloride (5.0 mL), rac-ethyl 1-(2-hydrox-
yethyl)nipecotinate (452 mg, 2.25 mmol), K2CO3 (774 mg,
5.60 mmol), MeCN (5.0 mL). The crude compound was purified by
flash column chromatography on silica (eluent pentane/Et2O 1 :1 to
pentane/Et2O 1 :1+20% triethylamine). Colourless semi-solid
(956 mg, 88%).
rac-Ethyl 1-[4-hydroxy-4,4-bis(4-methoxyphenyl)butyl]piperidine-
3-carboxylate (12 l): A mixture of 8 l (435 mg, 1.29 mmol), rac-ethyl
nipecotinate (233 mg, 1.42 mmol), K2CO3 (446 mg, 3.23 mmol) and
KI (21 mg, 0.13 mmol) in MeCN (5.0 mL) was irradiated in the
microwave at 80 °C for 24 h, filtered and reduced in vacuum. The
crude compound was purified by flash column chromatography on
silica (eluent pentane/Et2O 2 :1+5% triethylamine). Amorphous
slightly yellowish solid (374 mg, 66%).
rac-Ethyl 1-(2-{[4-(hydroxymethyl)phenyl]bis[4-methoxyphenyl]
methoxy}-ethyl)piperidine-3-carboxylate (12m): Sodium borohy-
dride (46 mg, 1.2 mmol) was added to a solution of 12a (254 mg,
0.480 mmol) in MeOH (7.5 mL) at 0 °C. The ice bath was removed
and stirring was continued at ambient temperature for 3 h. The
mixture was poured into water (30.0 mL) and extracted thrice with
Et2O (30.0 mL). The combined organic phases were dried over
MgSO4, filtered and reduced in vacuum. Colourless oil (226 mg,
89%).
rac-Ethyl 1-{2-[(4-{[(2-methoxy-2-oxoethyl)amino]methyl}phenyl)
bis(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylate
(12n): GP5 was followed using 12a (449 mg, 0.850 mmol), methyl
glycinate hydrochloride (212 mg, 1.69 mmol), sodium triacetoxybor-
ohydride (250 mg, 1.18 mmol), CH2Cl2 (5.0 mL). The crude com-
pound was purified by flash column chromatography on silica
(eluent isohexane/ethyl acetate 7 :3+5% triethylamine). Colourless
semi-solid (289 mg, 57%).
rac-Ethyl 1-{2-[(4-{[(3-ethoxy-3-oxopropyl)amino]methyl}phenyl)
bis(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylate
(12o): GP5 was followed using 12a (480 mg, 0.900 mmol), β-
alanine methyl ester hydrochloride (314 mg, 2.25 mmol), sodium
triacetoxyborohydride (267 mg, 1.26 mmol), CH2Cl2 (10.0 mL). The
crude compound was purified by flash column chromatography on
silica (eluent Et2O+4% triethylamine). Pale yellow oil (236 mg,
42%).
rac-Ethyl 1-(2-{[4-({[1-(ethoxycarbonyl)cyclopropyl]amino}meth-
yl)-phenyl]bis[4-methoxyphenyl]methoxy}ethyl)piperidine-3-car-
boxylate (12p): GP5 was followed using 12a (233 mg, 0.44 mmol),
ethyl 1-aminocyclopropanecarboxylate hydrochloride (145 mg,
0.88 mmol), sodium triacetoxyborohydride (131 mg, 0.620 mmol),
CH2Cl2 (2.0 mL). The crude compound was purified by flash column
chromatography on silica (eluent pentane/Et2O+4% triethylamine).
Colourless semi-solid (168 mg, 59%).
rac-Ethyl 1-{2-[(4-{[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]
methyl}-phenyl)bis(4-methoxyphenyl)methoxy]ethyl}piperidine-
3-carboxylate (12q): GP5 was followed using 12a (152 mg,
0.290 mmol), ethyl 2-amino-2-methylpropanoate hydrochloride
(96 mg, 0.57 mmol), sodium triacetoxyborohydride (85 mg,
0.40 mmol), CH2Cl2 (2.0 mL). The crude compound was purified by
flash column chromatography on silica (eluent pentane/Et2O 1 :1+
4% triethylamine). Colourless semi-solid (119 mg, 64%).
rac-4-{[4-({2-[3-(Ethoxycarbonyl)piperidin-1-yl]ethoxy}bis{4-meth-
oxy-phenyl}methyl)benzyl]amino}butanoic acid (12s): GP6 was
followed 4-aminobutanoic acid (83 mg, 0.80 mmol), 12a (213 mg,
0.40 mmol), sodium cyanoborohydride (37 mg, 0.56 mmol), MeOH
(5.0 mL). The crude compound was purified by flash column
chromatography on silica (eluent MeOH). Amorphous colourless
solid (100 mg, 40%).
rac-4-{[4-({2-[3-(Ethoxycarbonyl)piperidin-1-yl]ethoxy}bis{4-meth-
oxy-phenyl}methyl)benzyl]amino}benzoic acid (12 t): GP6 was
followed using 4-aminobutanoic acid (217 mg, 1.58 mmol), 12a
(420 mg, 0.790 mmol), sodium cyanoborohydride (73 mg,
1.1 mmol), MeOH (10.0 mL). The crude compound was purified by
flash column chromatography on silica (eluent MeCN/H2O 9 :1).
Amorphous slightly yellowish solid (132 mg, 25%).
Analytical data
The analytical data of the synthesized compounds 5a–t, 8a–l, 9c,
11, 12a–q and 12s–t are presented in the Supporting Information.
Biological evaluation
[3H]GABA uptake assays: The [3H]GABA uptake assays were
performed according to Kragler et al.[33] Cells were grown in
150 cm2 plates to a confluence of 70–90% up to passage 25. After
detachment the cells were centrifuged 5 min at 500×g, washed for
three times in phosphate buffered saline and, finally, resuspended
in Krebs buffer (2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4,
4.7 mM KCl, 11 mM glucose, 25 mM Tris, 119 mM NaCl, pH 7.2). The
uptake assays were performed with aliquots of the resulting cell
suspension (about 100000–200000 cells per well) in a total volume
of 250 μl in 96 well 2.2 mL deep well plates. The cells were
equilibrated for 25 min in Krebs buffer in the presence of the test
compound at 37 °C in a gently shaking water bath. In the case of
poor solubility of the test compounds all samples contained 1%
DMSO. After addition of 25 μl of a solution containing [3H]GABA
(2.22 TBq/mmol, ARC, St Louis, MO, USA) and unlabeled GABA in
Krebs (final concentration 8 nM [3H]GABA and 32 nM unlabeled
GABA for mGAT1, mGAT3, mGAT4 and 20 nM [3H]GABA and 20 nM
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unlabeled GABA for mGAT2) the cells were incubated for further
4 min (mGAT1, mGAT3, mGAT4) or 10 minutes (mGAT2), respec-
tively. The incubation was stopped by filtration through Sartorius
MGC micro glass fiber filters pre-soaked for 1 h in 0.9% NaCl by
means of a Brandell MWXR-96TI cell harvester (Brandell, Gaithers-
burg, MD, USA) under reduced pressure. The filters were rinsed two
times with cold 0.9% NaCl and subsequently transferred to 96 well
sample plates (Perkin Elmer LAS, Boston, MA, USA). After addition
of 200 μl Rotiszint Eco Plus (Roth, Karlsruhe, Germany) per well the
radioactivity was determined in a microbeta liquid scintillation
counter (Perkin Elmer LAS, Boston, MA, USA). Non-specific uptake
was determined in presence of 10 mM GABA for mGAT1, mGAT3
and mGAT4 or 100 mM GABA for mGAT2, respectively. The results
are expressed as means�S.E.M. of at least three separate experi-
ments, each carried out in triplicate.
MS Binding Assays: The MS Binding Assays were performed with
mGAT1 membrane preparations obtained from a stably mGAT1
expressing HEK293 cell line and NO711 as unlabeled marker in
competitive binding experiments as previously described in
detail.[34] In short, test compounds were investigated at 7 concen-
trations in presence of 10 nM NO 711 in competition experiments.
Non specific binding was defined as binding remaining in the
presence of 100 mM GABA. Incubation was terminated by transfer
of 200 μL per well onto a 96-well filter plate (Acroprep, glass fibre,
1.0 μm, 350 μL, Pall, Dreieich, Germany) with a 12 channel pipette.
After rapid vacuum-filtration the filters were washed with ice cold
0.9% NaCl (5×150 μL) and dried at 50 °C for 60 min. Afterwards,
the filters were eluted with 100 μL methanol containing [2H10]
NO711 (1.4 nM) as internal standard per well into a deep-well plate
by application of vacuum. This step was repeated twice resulting in
a total elution volume of 300 μL. Finally, a volume of 130 μL
ammonium formate buffer (10 mM, pH 7.0) was added per well and
the generated samples analyzed by LC-ESI-MS/MS using a API 3200
as described in detail previously.[40]
Conflict of Interest
The authors declare no conflict of interest.
Keywords: GABA uptake inhibitors · mGAT4 · medicinal
chemistry · neurochemistry · structure-activity relationships
[1] P. Krogsgaard-Larsen, Med. Res. Rev. 1988, 8, 1, 27–56.
[2] B. S. Meldrum, A. G. Chapman, Epilepsia 1999, 40, 9, 2–6.
[3] D. M. Treiman, Epilepsia 2001, 42, 8–12.
[4] S. R. Kleppner, A. J. Tobin, Expert Opin. Ther. Targets 2001, 5, 219–239.
[5] M. A. Daemen, G. Hoogland, J. M. Cijntje, G. H. Spincemaille, Neurosci.
Lett. 2008, 444, 112–115.
[6] P. Nuss, Neuropsychiatr. Dis. Treat. 2015, 11, 165–175.
[7] A. V. Kalueff, D. J. Nutt, Depression Anxiety 2007, 24, 495–517.
[8] K. L. Lanctot, N. Herrmann, P. Mazzotta, L. R. Khan, N. Ingber, J. Can.
Psychiatr. Assoc. 2004, 49, 439–453.
[9] Ł. Fijałkowski, K. Sałat, A. Podkowa, P. Zaręba, A. Nowaczyk, Eur. J.
Pharm. Sci. 2017, 96, 362–372.
[10] K. Sałat, A. Podkowa, P. Kowalczyk, K. Kulig, A. Dzubina, B. Filipek, T.
Librowski, Pharmacol. Rep. 2015, 67, 465–472.
[11] A. Schousboe, K. K. Madsen, M. L. Barker-Haliski, H. S. White, Neurochem.
Res. 2014, 39, 1980–1987.
[12] A. S. Kristensen, J. Andersen, T. N. Jørgensen, L. Sørensen, J. Eriksen, C. J.
Loland, K. Strømgaard, U. Gether, Pharmacol. Rev. 2011, 63, 3, 585–640.
[13] S. Bröer, U. Gether, Br. J. Pharmacol. 2012, 167, 2, 256–278.
[14] L. Shi, M. Quick, Y. Zhao, H. Weinstein, J. A. Javitch, Mol. Cell 2008, 30,
667–677.
[15] K. K. Madsen, R. P. Clausen, O. M. Larsson, P. Krogsgaard-Larsen, A.
Schousboe, H. S. White, J. Neurochem. 2009, 109, 139–144.
[16] N. O. Dalby, Eur. J. Pharmacol. 2003, 479, 127–137.
[17] B. Christiansen, A. K. Meinild, A. A. Jensen, H. Bräuner-Osbore, J. Biol.
Chem. 2007, 282, 19331–19341.
[18] L. A. Borden, Neurochem. Int. 1996, 29, 4, 335–356.
[19] Y. Zhou, N. C. Danbolt, Front. Endocrinol. 2013, 4, 165.
[20] S. A. Kempson SA, Y. Zhou Y, N. C. Danbolt, Front. Plant Physiol. 2014, 5,
159.
[21] Y. Zhou, S. Holmseth, R. Hua, A. C. Lehre, A. M. Olofsson, I. Poblete-
Naredo, S. A. Kempson, N. C. Danbolt, Am. J. Physiol. Ren. Physiol. 2012,
302, 313–328.
[22] K. K. Madsen, H. S. White, A. Schousboe, Pharmacol. Ther. 2010, 125,
394–401.
[23] I. E. Leppik, L. Gram, R. Deaton, K. W. Sommerville, Epilepsy Res. 1999,
33, 235–246.
[24] T. G. M. Dhar, L. A. Borden, S. Tyagarajan, K. E. Smith, T. A. Branchek, R. L.
Weinshank, C. Gluchowski, J. Med. Chem. 1994, 37, 2334–2342.
[25] J. Pabel, M. Faust, C. Prehn, B. Woerlein, L. Allmendinger, G. Höfner, K. T.
Wanner, ChemMedChem 2012, 7, 1245–1255.
[26] M. Petrera, T. Wein, L. Allmendinger, M. Sindelar, J. Pabel, G. Höfner,
K. T. Wanner ChemMedChem 2016, 11, 519–538.
[27] R. Schirrmacher, W. Hamkens, M. Piel, U. Schmitt, H. Lüddens, C. Hiemke,
F. Rösch, J. Labelled Compd. Radiopharm. 2001, 44, 627–642.
[28] L. J. S. Knutsen, K. E. Andersen, J. Lau, B. F. Lundt, R. F. Henry, H. E.
Morton, L. Nrum, H. Petersen, H. Stephensen, P. D. Suzdak, J. Med.
Chem. 1999, 42, 18, 3447–3462.
[29] G. C. Midya, A. Kapat, S. Maiti, J. Dash, J. Org. Chem. 2015, 80, 8, 4148–
4151.
[30] T. Ohwada, K. Shudo, J. Am. Chem. Soc. 1988, 110, 6, 1862–70.
[31] G. Speck, C. Eickmeier, S. Pestel, S. Germeyer, M. P. Pieper, S.
Breitenfelder, M. Grauert, PCT Int. Appl. 2007, 2003064418.
[32] A. F. Abdel-Magid, K. G. Carson, B. D. Harris, C. A. Maryanoff, R. D. Shah,
J. Org. Chem. 1996, 61, 3849–3862.
[33] A. Kragler, G. Höfner, K. T. Wanner, Eur. J. Med. Chem. 2008, 43, 2404–
2411.
[34] C. Zepperitz, G. Höfner, K. T. Wanner, ChemMedChem 2006, 1, 298–217.
[35] MarvinSketch, version 6.1.4; ChemAxon, Budapest (Hungary), http://
www.chemaxon.com/products/marvin/marvinsketch/ (accessed July 30,
2019).
[36] S. A. Hitchcock, L. D. Pennington, J. Med. Chem. 2006, 49, 7559–7583.
[37] J. Mensch, J. Oyarzabal, C. Mackie, P. Augustijns, J. Pharm. Sci. 2009, 98,
4429–4468.
[38] publication is to follow.
[39] W. C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 14, 2923–2925.
[40] G. Höfner, K. T. Wanner, J. Chromatogr. B 2010, 878, 1356–1364.
Manuscript received: December 20, 2019
Revised manuscript received: February 26, 2020
Accepted manuscript online: March 18, 2020
Version of record online: April 7, 2020
ChemMedChem
Full Papers
doi.org/10.1002/cmdc.201900719
771ChemMedChem 2020, 15, 756–771 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Dienstag, 28.04.2020
2009 / 161993 [S. 771/771] 1
